FO
ATXS

FT Options’s Astria Therapeutics ATXS Stock Holding History

FT Options’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-296
Closed -$64K – 288
2016
Q4 		$64K Hold
296
– – 0.07% 128
2016
Q3 		$109K Buy
296
+45
+18% +$11.9K 0.09% 156
2016
Q2 		$56K Buy
+251
New +$75.7K 0.05% 194

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

FT Options's ATXS Position: Q1 2017 in Review

FT Options sold out of Astria Therapeutics (ATXS) in Q1 2017, closing a stake of 296 shares — an estimated $64K sold.

FT Options first reported a position in ATXS in Q2 2016 and held it in 3 quarters. The position peaked at $109K in Q3 2016. 23 funds tracked by Wall St. Rank hold ATXS as of Q1 2017.

  • FT Options reported no remaining Astria Therapeutics position as of Q1 2017 after selling out during the quarter.
  • FT Options sold 296 Astria Therapeutics shares in Q1 2017, an estimated $64K.
  • FT Options first reported a position in Astria Therapeutics in Q2 2016 and held it in 3 quarters.
  • FT Options's Astria Therapeutics position peaked at $109K in Q3 2016.
  • 23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.